Skip to content
Review

Beyond the Generic Tumor: Engineering Patient-Specific Immune Ecosystems for Cancer.

Sep 2026 · Critical reviews in oncology/hematology · pp. 105611 · 0 citations · 93 references
Medicine

TL;DR

Current evidence supports personalized immunotherapy as a promising approach for improving the precision of cancer treatment, but its clinical application remains constrained by biological, technical, manufacturing, regulatory, and clinical challenges.

Abstract

Cancer immunotherapy has transformed the treatment landscape of malignancies; however, durable clinical responses remain limited by interpatient heterogeneity, tumor evolution, antigen loss, and variability in immune recognition. Advances in genomic sequencing, neoantigen discovery, immunopeptidomics, mRNA-based therapeutics, and cellular engineering have expanded opportunities for developing individualized immunotherapeutic strategies based on patient-specific tumor and immune characteristics. This review examines the state of personalized cancer immunotherapy, with emphasis on individualized neoantigen-specific therapies (iNeST), neoantigen vaccines, mRNA-based antigen delivery platforms, engineered T-cell approaches, and computational methods for antigen prioritization and immune-response prediction. We summarize the biological rationale, preclinical and clinical evidence, and limitations of these approaches, while considering their translational potential and clinical feasibility. We examine the relationships among tumor mutational landscapes, neoantigen immunogenicity, antigen processing and presentation, HLA restriction, immune-cell engineering, and computational immunology. We further assess key barriers to clinical implementation, including limitations in neoantigen prediction and validation, intratumoral heterogeneity, antigen evolution and loss, manufacturing complexity, scalability, regulatory requirements, and the need for prospective clinical validation. Overall, current evidence supports personalized immunotherapy as a promising approach for improving the precision of cancer treatment, but its clinical application remains constrained by biological, technical, manufacturing, regulatory, and clinical challenges. Future progress will require more accurate and experimentally validated neoantigen identification, improved computational and immunologic modeling, robust manufacturing and quality-control processes, and prospective clinical studies demonstrating safety, feasibility, and therapeutic benefit. This review evaluates the current evidence, identifies knowledge gaps, and outlines priorities for the responsible clinical development of individualized cancer immunotherapy.

View source

Similar papers

Review Sep 2026

Therapeutic Cancer Vaccines: Classification, Mechanisms, Challenges and Future Perspectives.

BACKGROUND With the rapid advancements in oncology, immunology, and molecular biology, immunotherapy has emerged as a cornerstone of anti-tumor treatment, complementing traditional modalities such as surgery, radiotherapy, and chemotherapy. Therapeutic cancer vaccines are a promising immunotherapy strategy that deliver...

Ju-Wei Gao, Yue Sun, Zi-Jing Han et al. · 0 citations
Review Open access Sep 2026

Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade

By integrating molecular vaccine design with tumor evolution, immune-contexture remodeling, and checkpoint sensitivity, this review identifies determinants that may distinguish successful immune priming from durable therapeutic efficacy and outlines priorities for biomarker-guided patient selection and future combinati...

T. Demircan, Berna Yıldırım, Halil İbrahim Ünsal et al. · 0 citations
Review Open access Oct 2026

Progress on therapeutic mRNA vaccines for cancer

Therapeutic mRNA vaccines are a clinically validated cancer immunotherapy platform using in vitro transcribed mRNA encoding tumor antigens to induce durable anti-tumor immunity. Advances in mRNA engineering, lipid nanoparticle (LNP) delivery, and immunomodulatory combinations have propelled this approach from preclinic...

Si-Yu Wu, Hua-Rong Liao, Wei Zhang · 0 citations
Review Oct 2026

Rewiring the Tumor-Immune Ecosystem: Extracellular Vesicles in the Next Era of Cancer Immunotherapy.

Cancer immunotherapy has transformed oncology by enabling immune-mediated tumor elimination; however, durable responses remain limited, particularly in solid tumors due to antigen heterogeneity, immunosuppressive tumor microenvironment, and adaptive resistance mechanisms. To overcome these barriers, therapeutic paradig...

A. Bahr, Youssef Basem, A. Alaa et al. · 0 citations
Review Open access Oct 2026

Dynamic Immune Responsiveness in Breast Cancer: Tumor Microenvironment Plasticity, Therapeutic Timing, and Clinical Translation

A precision-immunotherapy framework is proposed in which treatment selection and sequencing could be informed by evolving immune states, and this framework complements established treatment approaches and defines testable hypotheses for prospective clinical studies.

S. M. Nashir Udden, Monira Obaid, Laurentiu M. Pop et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.